James E. Goodnight
-
- Sarcoma Diagnosis and Treatment 8
- Oncology top 10%
- Vascular Tumors and Angiosarcomas 4
- Pancreatic and Hepatic Oncology Research 4
- Cancer Immunotherapy and Biomarkers 4
- Rheumatology top 5%
- Surgery top 5%
- Esophageal Cancer Research and Treatment 4
- Esophageal and GI Pathology 4
-
- Immunotherapy and Immune Responses 4
-
- Breast Cancer Treatment Studies 4
James E. Goodnight
44 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 94
- Pulmonary and Respiratory Medicine 668
- Oncology 444
- Rheumatology 227
- Pathology and Forensic Medicine 246
- Surgery 555
Countries citing papers authored by James E. Goodnight
This map shows the geographic impact of James E. Goodnight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Goodnight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Goodnight more than expected).
Fields of papers citing papers by James E. Goodnight
This network shows the impact of papers produced by James E. Goodnight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Goodnight. The network helps show where James E. Goodnight may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James E. Goodnight, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 6 | |
| 2 | 2009 | 52 | |
| 3 | 2008 | 48 | |
| 4 | 2006 | 20 | |
| 5 | Practice guidelines for esophageal cancer. | 2006 | 1 |
| 6 | 2005 | 130 | |
| 7 | 2004 | 1 | |
| 8 | 2004 | 30 | |
| 9 | 2004 | 12 | |
| 10 | 2003 | 71 | |
| 11 | 2002 | 23 | |
| 12 | 2001 | 14 | |
| 13 | 2001 | 12 | |
| 14 | 2001 | 52 | |
| 15 | 1994 | 5 | |
| 16 | 1993 | 12 | |
| 17 | 1992 | 19 | |
| 18 | 1992 | 16 | |
| 19 | 1990 | 24 | |
| 20 | Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. | 1980 | 23 |
About James E. Goodnight
James E. Goodnight is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Dermatology, Surgery and Cancer Research, having authored 46 papers that have together received 1.4k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (8 papers), Vascular Tumors and Angiosarcomas (4 papers), Esophageal Cancer Research and Treatment (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Immunotherapy and Immune Responses (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Breast Cancer Treatment Studies (4 papers) and Esophageal and GI Pathology (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (668 citations), Oncology (444 citations), Rheumatology (227 citations), Pathology and Forensic Medicine (246 citations) and Surgery (555 citations). James E. Goodnight has collaborated with scholars based in United States. Frequent co-authors include Vijay P. Khatri, Frederick R. Eilber, K.G. Patterson, A. E. Giuliano, J J Eckardt, Philip D. Schneider, Donald L. Morton, Richard J. Bold, Joseph M. Quagliana and Vafa Ghaemmaghami. Their work appears in journals such as Cancer, Journal of Surgical Oncology, Surgical Clinics of North America, Diseases of the Colon & Rectum and Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.